羚锐制药(600285) - 2020 Q3 - 季度财报

Financial Performance - Operating revenue for the first nine months was ¥1,749,409,044.15, representing a year-on-year increase of 3.45%[18] - Net profit attributable to shareholders of the listed company was ¥269,569,972.01, up by 2.96% compared to the same period last year[18] - Basic earnings per share increased by 5.79% to ¥0.475[20] - Total operating revenue for Q3 2020 reached ¥574,856,375.38, an increase of 10.04% compared to ¥522,332,617.51 in Q3 2019[47] - Net profit for Q3 2020 was ¥91,672,135.06, representing a 17.06% increase from ¥78,002,179.93 in Q3 2019[54] - The net profit for the first three quarters of 2020 was ¥268,309,852.21, a 2.66% increase from ¥260,585,088.58 in the first three quarters of 2019[54] - The total profit for Q3 2020 was ¥105,668,349.22, an increase of 0.20% compared to ¥92,484,137.72 in Q3 2019[54] Assets and Liabilities - Total assets at the end of the reporting period reached ¥3,380,280,274.73, an increase of 1.95% compared to the end of the previous year[18] - Total current assets rose to ¥1,878,064,473.38, up from ¥1,754,360,754.13, indicating an increase of 7.06%[34] - Current liabilities totaled ¥1,028,411,217.55, compared to ¥1,013,790,659.56, reflecting an increase of about 1.3%[39] - Total liabilities amounted to ¥1,100,366,942.14, slightly up from ¥1,095,331,468.09, indicating a growth of around 0.3%[39] - Shareholders' equity reached ¥2,279,913,332.59, compared to ¥2,220,446,251.23, showing an increase of approximately 2.7%[39] - Non-current liabilities totaled ¥71,955,724.59, down from ¥81,540,808.53, reflecting a decrease of approximately 11.7%[39] Cash Flow - The net cash flow from operating activities for the first nine months was ¥338,148,814.79, a decrease of 7.20% year-on-year[18] - The cash inflow from operating activities for the first three quarters of 2020 was ¥1.901 billion, compared to ¥1.867 billion in the same period of 2019, indicating a growth of about 1.8%[68] - The net cash flow from investing activities was -CNY 72,712,668.28, worsening from -CNY 60,262,867.44 in the same period last year[75] - Cash inflow from investing activities totaled CNY 291,095,014.15, significantly higher than CNY 73,730,701.88 in 2019, marking an increase of approximately 294.5%[75] Shareholder Information - The total number of shareholders at the end of the reporting period was 39,626[22] - The largest shareholder, Henan Lingrui Group, held 21.4% of the shares, with 121,817,898 shares[22] Research and Development - Research and development expenses increased by 45.49% to ¥49,662,393.86 from ¥34,135,737.36, highlighting a focus on innovation[28] - Research and development expenses for Q3 2020 amounted to ¥14,894,508.78, a significant increase of 72.67% from ¥8,646,421.54 in Q3 2019[51] Government Subsidies - The company reported a government subsidy of ¥4,739,436.92 for the current period, which is closely related to its normal business operations[21] Financial Management - The company's short-term borrowings decreased by 54.44% to ¥61,511,000.00 from ¥135,000,000.00, indicating improved financial management[28] - The company's total liabilities decreased, with a notable reduction in short-term borrowings, enhancing its financial stability[28]